2. Protein Tyrosine Kinase/RTK NF-κB Metabolic Enzyme/Protease Immunology/Inflammation Apoptosis Cytoskeleton PI3K/Akt/mTOR Stem Cell/Wnt MAPK/ERK Pathway
  3. PDGFR Reactive Oxygen Species (ROS) Ferroptosis Myosin Akt mTOR ERK
  4. MT-125

MT-125 is a specific and well-tolerated inhibitor of non-muscle myosin IIA (Ki,NMIIA = 2.7 μM) and IIB (EC50 = 1.7 μM). MT-125 can pass through the blood-brain barrier. MT-125 induces ferroptosis and DNA damage by increasing the levels of reactive oxygen species (ROS) within tumor cells. MT-125 can enhance the PDGFR signaling pathway. MT-125 can be used for research on glioblastoma[1].

For research use only. We do not sell to patients.

MT-125 Chemical Structure

MT-125 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

MT-125 Related Antibodies

Top Publications Citing Use of Products

View All PDGFR Isoform Specific Products:

View All Isoforms
PDGFR PDGFRβ PDGFRα

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All mTOR Isoform Specific Products:

View All Isoforms
mTOR mTORC1 mTORC2

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

MT-125 is a specific and well-tolerated inhibitor of non-muscle myosin IIA (Ki,NMIIA = 2.7 μM) and IIB (EC50 = 1.7 μM). MT-125 can pass through the blood-brain barrier. MT-125 induces ferroptosis and DNA damage by increasing the levels of reactive oxygen species (ROS) within tumor cells. MT-125 can enhance the PDGFR signaling pathway. MT-125 can be used for research on glioblastoma[1].

IC50 & Target

PDGFRα

 

In Vitro

MT-125 (5 μM, 8 h) significantly inhibits the invasive ability of one murine (MES1861) and three human (187, 190, and L1) Glioblastoma (GBM) cell lines[1].
MT-125 (5 μM, 48 h) leads to 12 %-25 % cell multinucleation in 10 human GBM cells[1].
MT-125 (0.1-10 μM; 96 h) produces over 90 % cytotoxicity in various mouse and human GBM cell lines[1].
MT-125 increase reactive oxygen species (ROS) and lipid peroxidation levels in L1 cells[1].
MT-125 (4 μM) can induce ferroptosis and ferroptosis inhibitors can reverse its cytotoxicity in Trp53(‒/‒) cells[1].
MT-125 (5 μM, 48 h) significantly increase PDGFRα expression and activation of downstream signaling pathways in Trp53(‒/‒) cells[1].
MT-125 (5 μM, 48 h) regulates the MAPK signaling pathway by inhibiting NMIIA in Trp53(‒/‒) cells[1].
MT-125 (5 μM, 48 h) exhibits synergistic effects with carcinogenic kinase inhibitors in Trp53(‒/‒) cells[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

MT-125 Related Antibodies

Cell Viability Assay[1]

Cell Line: murine (TRP53(-/-), Pten(-/-), TRP53/Pten(-/-)) and human (L1, L0, GBM1A, 612, QNS120, QNS166, QNS315) GBM cell lines
Concentration: 3.3-7.3 μM
Incubation Time: 96 h
Result: Significantly inhibited the GBM cell lines.

Western Blot Analysis[1]

Cell Line: Trp53(‒/‒) cells
Concentration: 5 μM
Incubation Time: 48 h
Result: Effectively enhanced activation of PDGFRα, AKT, mTOR, ERK1/2, and SRC.
In Vivo

MT-125 (10 mg/kg; s.c.; once daily; for 2 weeks) demonstrates low toxicity in vivo for the C57BL/6 mice[1].
MT-125 (20 or 40 mg/kg, s.c.; once daily; for 7 days) does not cause any adverse effects related to medication and does not affect age-related weight changes in the C57BL/6 mice[1].
MT-125 (7.5, 15, or 30 mg/kg; s.c.; once daily; for 28 days) maintain good tolerability in repeated dose toxicology studies in the C57BL/6 mice[1].
MT-125 (10 mg/kg; i.p.; once daily; for 4 weeks) synergizes with oncogenic kinase inhibitors and can significantly inhibit the growth of tumor cells in the C57BL/6 mice with Trp53(‒/‒) tumors[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: C57BL/6 mice (8-10 weeks; 25-35 g)[1]
Dosage: 10 mg/kg
Administration: Subcutaneous injection (s.c.); once daily for 2 weeks
Result: Had good tolerance and the weight and hematological indicators of mice were within normal range.
Animal Model: C57BL/6 mice (8-10 weeks; 25-35 g)[1]
Dosage: 20 or 40 mg/kg
Administration: Subcutaneous injection (s.c.); once daily for 7 days
Result: Maintained normal body weight and hematological parameters within the normal range in mice.
Animal Model: C57BL/6 mice (8-10 weeks; 25-35 g)[1]
Dosage: 7.5, 15, or 30 mg/kg
Administration: Subcutaneous injection (s.c.); once daily for 28 days
Result: Did not cause any obvious or lasting adverse health effects.
Animal Model: C57BL/6 mice with Trp53(‒/‒) tumors (8-10 weeks; 25-35 g)[1]
Dosage: 10 mg/kg, co-incubation with Paxalisib (HY-19962)
Administration: Intraperitoneal injection (i.p.); once daily for 4 weeks
Result: Markedly reduced tumor size to an isolated nest of HA-positive cells and prolonged survival rate.
Molecular Weight

393.87

Formula

C22H20ClN3O2
SMILES

CC1=CC2=C(N=C(N(C3=CC4=C(N=C(C)C=C4)C=C3)CC5)[C@]5(O)C2=O)C=C1.Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

MT-125 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

MT-125MT125MT 125PDGFRReactive Oxygen Species (ROS)FerroptosisMyosinAktmTORERKPlatelet-derived growth factor receptorPKBProtein kinase BMammalian target of RapamycinExtracellular signal regulated kinasesferroptosisROSanticancerglioblastomaMAPKPI3KInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
MT-125
Cat. No.:
HY-174406
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.